Clinical Trial Update: ACPs in Severe PAD/CLI by Direct Intramuscular Injection [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ACPs delivered by direct intramuscular injection for severe peripheral arterial disease and critical limb ischemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Arterial Disease

Drugs mentioned

• ACPs (adipose-derived progenitor cells) (adipose-derived progenitor cells)

Snippet

Sponsor: TheraVitae Ltd. | Conditions: Peripheral Arterial Disease, Critical Limb Ischemia | Phase 1 | Status: COMPLETED